UK-432,097
Encyclopedia
UK-432,097 is a drug developed by Pfizer
for the treatment of chronic obstructive pulmonary disease
, which acts as a potent and selective agonist
of the adenosine A2A receptor
. It was discontinued from clinical trial
s following poor efficacy results, but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.
Pfizer
Pfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
for the treatment of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease , also known as chronic obstructive lung disease , chronic obstructive airway disease , chronic airflow limitation and chronic obstructive respiratory disease , is the co-occurrence of chronic bronchitis and emphysema, a pair of commonly co-existing diseases...
, which acts as a potent and selective agonist
Agonist
An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Agonists often mimic the action of a naturally occurring substance...
of the adenosine A2A receptor
Adenosine A2A receptor
The adenosine A2A receptor, also known as ADORA2A, is an adenosine receptor, but also denotes the human gene encoding it.-Structure:This protein is a member of the G protein-coupled receptor family which possess seven transmembrane alpha helices...
. It was discontinued from clinical trial
Clinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
s following poor efficacy results, but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.